Skip to content

Efficacy and fMRI mechanism of acupuncture for bipolar disorder in a major depressive episode

Efficacy and fMRI mechanism of acupuncture for bipolar disorder in a major depressive episode

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200061372
Enrollment
Unknown
Registered
2022-06-22
Start date
2022-06-21
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar disorder

Interventions

Study group:Acupuncture therapy
Control group:Sham acupuncture stimulation

Sponsors

Beijing Anding Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: ? Meet the diagnostic criteria of bipolar depression; ? Gender is not limited and the age is between 18-60 years old; right-handed; ? HAMD-24 scale score =20 points; ? Those who have not taken psychotropic drugs, or psychotropic drugs have been cleaned for one week as required, or have been on cross-drug for one week; ? No metal in the body, no claustrophobia or other contraindications for MRI; ? Voluntary participation in clinical research and sign the informed consent by themselves and/or their guardians.

Exclusion criteria

Exclusion criteria: ? Mental disorders caused by organic brain diseases, or comorbidity of mental disorders related to psychoactive substances, or comorbidity of other types of mental disorders; ? Severe asymmetry of the anatomical structure of the head, or definite lesions are found in the MRI scan; ? Those who have aggressive behavior and strong suicidal tendencies; ? Those with severe physical disease or severe liver and kidney dysfunction; ? Those who experienced obvious discomfort such as fainting during acupuncture treatment; ? Pregnant or lactating women; ? Those who have participated in similar neuroimaging trials within one month; ? Those who received non-convulsive electroconvulsive therapy in the past one month.

Design outcomes

Primary

MeasureTime frame
HAMD-24 score;

Secondary

MeasureTime frame
HAMA score;Clinical Global Impression Scale score;Side Effects Scale score;

Countries

China

Contacts

Public ContactPei Chen
bettereveryday@163.com+86 10 58303111

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026